# Pizarra — PT-pseudo_c39e94a13920 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c39e94a13920
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 12.4 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.58 ng/mL/yr
  - Prior PSA: 11.3 ng/mL
  - Prostate volume: 149.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.58010316 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: atorvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.

Vitals: weight 91 kg, height 178 cm, BMI 28.7, BP 128/89 mmHg, HR 70 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Clinical review sought due to sustained PSA elevation and a previously positive biopsy result.

History: A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history.

Physical examination: DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent.

Patient info: graphic designer; Married; Lives with partner; adult children visit weekly.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 4 units / week; exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.47 +/- 0.18   (95% CI 0.11-0.83)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.18  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What is the prior grade, surveillance pathway, and agreed management plan?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or deferral, as the initial panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context of the patient's history, such as the prior positive biopsy result, the specific PSA velocity (1.58 ng/mL/yr), and the specific PI-RADS 3 score in relation to the guideline's risk matrix.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.47 +/- 0.18. This suggestion could be wrong because the classifier's high aleatoric uncertainty (H=1.00) indicates the model cannot distinguish between the two outcomes based on the input, suggesting the panel is genuinely insufficient. Furthermore, the prior ignores the guideline criterion that states the decision must come from the retrieved documents, which the prior failed to do.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What is the prior grade, surveillance pathway, and agreed management plan?
previous_notes - What is the prior grade, surveillance pathway, and agreed management plan?
previous_notes - What is the prior grade, surveillance pathway, and agreed management plan?
GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents, specifically assessing if the prior grade is documented, if the lesion changed against a previous MRI, and if surveillance re-biopsy is due.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division | Amsterdam UMC (VUmc) | 28 Dec 2024
The gland measures 149.0 mL in volume, showing marked enlargement with a prominent transition zone and mild peripheral zone atrophy. A focal area is noted in the right peripheral zone at the mid-gland level, spanning roughly 14 x 11 x 10 mm. T2-weighted sequences display intermediate signal intensity within this region. Diffusion-weighted imaging (b-value 1500) reveals intermediate signal coupled with moderately reduced ADC values, indicating restricted diffusion yet falling short of definitive malignant features. There is no evidence of extraprostatic extension or seminal vesicle invasion. Impression: PI-RADS 3 lesion located in the right peripheral zone at the mid-gland level. csPCa probability: 0.58010316.

get_psa_trend
[{"date": "Aug 2023", "val": 2.2}, {"date": "Dec 2023", "val": 3.4}, {"date": "Apr 2024", "val": 5.2}, {"date": "Aug 2024", "val": 8.0}, {"date": "Jan 2025", "val": 12.4}]

get_previous_notes
[{"date": "13 Jul 2023", "author": "Dr. M. Jansen (GP)", "text": "August 2023 laboratory results recorded a PSA level of 7.1 ng/mL, marking a continuation of the initial borderline elevation observed earlier that year. Persistent values exceeding the laboratory reference range, combined with the patient\u2019s age, prompted a urological referral for multiparametric MRI and further risk stratification. Routine blood work, including renal function and full blood count, remained within stable parameters."}]

NOT RETRIEVED
The laboratory results panel was deliberately left closed as the moderator's agenda did not require it, and opening it would not directly address the specific questions regarding prior grade, lesion change, or surveillance status.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- PSA trend shows a clear rising trajectory: 2.2 (Aug 2023) to 12.4 (Jan 2025).
- The MRI shows a PI-RADS 3 lesion, which is equivocal and requires further characterization given the rising PSA.

AGAINST Sampling this patient now:
- Prior biopsy result is documented as 'Positive' (no grade provided).
- The MRI shows an unchanged lesion status (PI-RADS 3) compared to the prior assessment context.

WHERE THIS LEANS
The rising PSA trend and the presence of a PI-RADS 3 lesion suggest that further characterization, likely via biopsy, is warranted to resolve the uncertainty surrounding the prior positive diagnosis.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, showing a clear rising PSA trend and a PI-RADS 3 lesion, supports the leaning towards biopsy, despite the prior positive biopsy. The record is sufficient to proceed to the final decision.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context of the patient's history, such as the prior positive biopsy result, the specific PSA velocity (1.58 ng/mL/yr), and the specific PI-RADS 3 score in relation to the guideline's risk matrix.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.47 +/- 0.18. This suggestion could be wrong because the classifier's high aleatoric uncertainty (H=1.00) indicates the model cannot distinguish between the two outcomes based on the input, suggesting the panel is genuinely insufficient. Furthermore, the prior ignores the guideline criterion that states the decision must come from the retrieved documents, which the prior failed to do.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What is the prior grade, surveillance pathway, and agreed management plan?
previous_notes - What is the prior grade, surveillance pathway, and agreed management plan?
previous_notes - What is the prior grade, surveillance pathway, and agreed management plan?
GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents, specifically assessing if the prior grade is documented, if the lesion changed against a previous MRI, and if surveillance re-biopsy is due.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division | Amsterdam UMC (VUmc) | 28 Dec 2024
The gland measures 149.0 mL in volume, showing marked enlargement with a prominent transition zone and mild peripheral zone atrophy. A focal area is noted in the right peripheral zone at the mid-gland level, spanning roughly 14 x 11 x 10 mm. Impression: PI-RADS 3 lesion located in the right peripheral zone at the mid-gland level. csPCa probability: 0.58010316.

get_psa_trend
[{"date": "Aug 2023", "val": 2.2}, {"date": "Dec 2023", "val": 3.4}, {"date": "Apr 2024", "val": 5.2}, {"date": "Aug 2024", "val": 8.0}, {"date": "Jan 2025", "val": 12.4}]

get_previous_notes
[{"date": "13 Jul 2023", "author": "Dr. M. Jansen (GP)", "text": "August 2023 laboratory results recorded a PSA level of 7.1 ng/mL, marking a continuation of the initial borderline elevation observed earlier that year. Persistent values exceeding the laboratory reference range, combined with the patient\u2019s age, prompted a urological referral for multiparametric MRI and further risk stratification. Routine blood work, including renal function and full blood count, remained within stable parameters."}]

NOT RETRIEVED
The laboratory results panel was deliberately left closed as the moderator's agenda did not require it, and opening it would not directly address the specific questions regarding prior grade, lesion change, or surveillance status.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- PSA trend shows a clear rising trajectory: 2.2 (Aug 2023) to 12.4 (Jan 2025).
- The MRI shows a PI-RADS 3 lesion, which is equivocal and requires further characterization given the rising PSA.

AGAINST Sampling this patient now:
- Prior biopsy result is documented as 'Positive' (no grade provided).
- The MRI shows an unchanged lesion status (PI-RADS 3) compared to the prior assessment context.

WHERE THIS LEANS
The rising PSA trend and the presence of a PI-RADS 3 lesion suggest that further characterization, likely via biopsy, is warranted to resolve the uncertainty surrounding the prior positive diagnosis.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fully addressed by retrieving the radiology report, PSA trend, and previous notes. The evidence leans towards biopsy due to the rising PSA and PI-RADS 3 finding, despite the prior positive biopsy. The disagreement remains about the final interpretation of this evidence.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The conference reached a split between deferral and biopsy, with the evidence leaning towards biopsy due to the rising PSA trend (from 2.2 to 12.4 ng/mL) and the presence of a PI-RADS 3 lesion. The statistical prior suggested no biopsy, but the retrieved PSA trajectory and imaging findings overturned this by suggesting further characterization is warranted. Since the guideline criterion abstained, the decision rests on the retrieved evidence, which supports proceeding with biopsy to resolve the uncertainty surrounding the prior positive diagnosis.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
